Table 5 Cellular models demonstrating the importance of UPR in cancer chemotherapy resistance

From: Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers

Tumor origin	Materials	Chemotherapy	Methods	GRP78	IRE1α	XBP1	XBP1s	ATF6	PERK	eIF2α	ATF4	Others	Comments	Ref.
Bladder	T24/83	Etoposide, doxorubicin, camptothecin	WB	+									Associated with resistance to apoptosis	¹¹⁶
Bone	MG-63, SaOS-2	Cisplatin	WB	+								(1)	Associated with resistance to apoptosis	¹¹⁷
Brain	U87	Temozolomide	WB	+									Increased with ER stress (DTT)	⁴⁶
	U87 and U251	Temozolomide	WB	+								(1)		⁴⁷
	LN229	Temozolomide, camptothecin, 5-FU	WB	+									Associated with resistance to apoptosis	⁴⁷
	A172 and LNZ308	Etoposide, cisplatin	IHC	+									Associated with resistance to apoptosis	⁴⁸
	U87 and U251	Temozolomide						+			+	(2)	Associated with radicol-induced apoptosis	¹¹⁸
Breast	MCF-7	Doxorubicin	WB	+								(3)		¹¹⁹
	T47D	Estrogen	Q-PCR, WB	+			+				+	(4)		⁵²
	MCF-7	Estrogen	Q-PCR, WB	+	+	+	+	+	+	+		(5)		⁵²
	MCF-7 xenograft	Estrogen	Q-PCR	+	−	−	+	−	−	+		(6)		⁵²
	293T, MCF-7	Etoposide	WB	+									Associated with BIK interaction	¹²⁰
	MCF-7, T47D	Fulvestrant	WB			+	+							¹²¹
	LCC1, LCC9	Fulvestrant	WB	+			+				+	(7)	Associated with autophagy	¹²²
	LCC9, MCF-7	Fulvestrant	WB			+	+						Associated with resistance to apoptosis	¹²³
	MDA-M35, T47D, MCF-7	Quercetin	Q-PCR, WB	+				+				(8)		¹²⁴
	MCF-7	Paclitaxel	WB	+									Associated with resistance to apoptosis	¹²⁵
	T47D	Tamoxifen	WB	+										⁵¹
	MCF-7, T47D MCF-7 xenograft	Tamoxifen Tamoxifen	RT–PCR, WB WB				+ +					(9)	Decreased resistance with IRE1 inhibitor decreased with IRE1 inhibitor	⁵³
	MCF-7, T47D	Tamoxifen	WB			+	+							¹²¹
	MCF-7 xenograft	Tamoxifen	WB			+	+							¹²¹
	Rat DMBA-induced mammary tumors	Tamoxifen	WB	+	+						+	(1)	Associated with autophagy	¹²⁶
	SKBr3	Trastuzumab	Q-PCR, ELISA	+								(10)	Increased with ER stress (Tg)	¹²⁷
Cervix	SiHa-derived stem-like cells	Cisplatin	RT–PCR, WB	+			+					(11)	increased apoptosis with IRE1 inhibitor	¹²⁸
Colorectal	Colo205, HCT116, SW480, SW626	Cisplatin, 5-FU	WB	+									Associated with resistance to apoptosis	⁵⁴
	HCT116 HT29	5-FU										(12)	Associated with resistance to apoptosis	⁵⁷
Kidney	A498, ACHN	Doxorubicin, 5-FU	IHC	+									Associated to cell cycle control	⁷¹
Liver	HepG2	Doxorubicin	RT–PCR, WB	+									Increased survival under glucose privation	⁶⁰
	7741, HepG2 and 7741 xenograft	Doxorubicin, VP-16	IHC, WB	+									Correlated with CD147 expression	⁶²
	HepG2, MHCC97	Sorafenib					+					(9)	Associated with resistance to apoptosis-dependent of RACK expression	⁷²
Lung	PC13, PC14	Doxorubicin	WB	+									Associated with resistance to apoptosis	⁶⁴
Ovary	PEO4	Estrogen	Q-PCR, WB	+			+							⁵²
	OVCAR-3	Paclitaxel	WB	+									Associated with resistance to apoptosis	¹²⁵
Skin	Hep3 (dormant versus tumorigene)	Etoposide, doxorubicin	Q-PCR, WB	+								(13)	Associated with resistance to apoptosis	¹²⁹
Others	CHO (hamster)	Etoposide, doxorubicin, camptothecin	WB	+									Associated with resistance to apoptosis	¹¹⁶
	CHO (hamster)	Etoposide	WB	+									Increased under ER stress (tg)	¹³⁰
	NIH3T3	Etoposide	WB	+									Increased under ER stress (tg)	¹³⁰

Abbreviations: ATF, activating transcription factor; BIK, Bcl-2-interacting killer; DTT, dithiothreitol; eIF2α, eukaryotic initiation factor 2α; ERO1L, ER oxidoreduction 1-like; 5-FU, 5-fluorouracil; FRP, glucose-regulated protein; HSP, heat-shock protein; IHC, immunohistochemistry; IRE1α, inositol requiring enzyme 1α; JNK, c-Jun N-terminal protein kinase; LCN2, lipocalin 2; PDI, protein disulfide isomerase; PERK, PKR-like endoplasmic reticulum kinase; Q-PCR, quantitative PCR; RT–PCR, reverse transcriptase–PCR; Tg, thapsigargin; UPR, unfolded protein response; WB, western blot; XBP, X-box binding protein.
(1) CHOP(+).
(2) calnexin(+), calreticulin(+), CHOP(+), GRP94(+), PDI(−), phosphorylated IRE1α, PERK and eIF2α(+).
(3) CHOP(+), phosphorylated PERK.
(4) Decreased CHOP, cleaved ATF6, phosphorylated PERK and eIF2α.
(5) DNAJC3, ERO1LB, GRP94.
(6) CHOP(+), DNAJC3(−), ERO1Lb(−), GADD34(+).
(7) CHOP(+), GRP94(+), cleaved ATF6, phosphorylated eIF2α.
(8) CHOP(+), phosphorylated eIF2α and JNK.
(9) Phosphorylated IRE1α.
(10) CHOP(+), LCN2(+).
(11) Phosphorylated eIF2α.
(12) Calnexin(+).
(13) HSP47(+), PDI(+), phosphorylated PERK and eIF2.

Back to article page

Table 5 Cellular models demonstrating the importance of UPR in cancer chemotherapy resistance

Search

Quick links